Skip to main content
Top
Published in: Quality of Life Research 8/2013

Open Access 01-10-2013

Empirically driven definitions of “good,” “moderate,” and “poor” levels of functioning in the treatment of schizophrenia

Authors: Haya Ascher-Svanum, Diego Novick, Josep Maria Haro, Jaume Aguado, Zhanglin Cui

Published in: Quality of Life Research | Issue 8/2013

Login to get access

Abstract

Purpose

This study used an empirical approach to identify and validate the classification of patients with schizophrenia in “good,” “moderate,” or “poor” functioning groups based on the assessment of functional measures.

Methods

Using data from a study of schizophrenia outpatients, patients were classified into functional groups using cluster analysis based on the Heinrich–Carpenter Quality of Life Scale (QLS), the 36-item Short-Form Health Survey (SF-36) Mental Component Summary Score, and a productivity measure. A three-cluster solution was chosen. Concurrent, convergent, and discriminant validity were assessed. Criteria for classifying patient functioning as “good,” “moderate,” or “poor” were established using classification and regression tree analysis.

Results

The three clusters consistently differentiated patients on the QLS, SF-36 Mental Component Summary Score, and productivity measure. The clusters also differed on other functional measures and were concordant with previous functional classifications. Concurrent, convergent, and discriminant validity were good. “Good” functioning was identified as a QLS total score ≥84.5; “moderate” and “poor” functioning were separated by a cutoff score of 15.5 on the QLS intrapsychic foundation domain. Sensitivity ranged from 86 to 93 % and specificity from 89 to 99 %.

Conclusions

The heterogeneity in functioning of schizophrenia patients can be classified reliably in an empirical manner using specific cutoff scores on commonly used functional measures.
Literature
1.
go back to reference McGurk, S. R., Lee, M. A., Jayathilake, K., & Meltzer, H. Y. (2004). Cognitive effects of olanzapine treatment in schizophrenia. Medscape General Medicine, 6, 27.PubMed McGurk, S. R., Lee, M. A., Jayathilake, K., & Meltzer, H. Y. (2004). Cognitive effects of olanzapine treatment in schizophrenia. Medscape General Medicine, 6, 27.PubMed
2.
go back to reference Lauriello, J., Lenroot, R., & Bustillo, J. R. (2003). Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia. Psychiatric Clinics of North America, 26, 191–211.PubMedCrossRef Lauriello, J., Lenroot, R., & Bustillo, J. R. (2003). Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia. Psychiatric Clinics of North America, 26, 191–211.PubMedCrossRef
3.
go back to reference Lenroot, R., Bustillo, J. R., Lauriello, J., & Keith, S. J. (2003). Integrated treatment of schizophrenia. Psychiatric Services, 54, 1499–1507.PubMedCrossRef Lenroot, R., Bustillo, J. R., Lauriello, J., & Keith, S. J. (2003). Integrated treatment of schizophrenia. Psychiatric Services, 54, 1499–1507.PubMedCrossRef
4.
go back to reference Awad, A. G., & Voruganti, L. N. (2008). The burden of schizophrenia on caregivers: a review. Pharmacoeconomics, 26, 149–162.PubMedCrossRef Awad, A. G., & Voruganti, L. N. (2008). The burden of schizophrenia on caregivers: a review. Pharmacoeconomics, 26, 149–162.PubMedCrossRef
5.
go back to reference Cramer, J. A., & Spilker, B. (1998). Quality of life and pharmacoeconomics: An introduction. Philadelphia, PA: Lippincott-Raven Publishers. Cramer, J. A., & Spilker, B. (1998). Quality of life and pharmacoeconomics: An introduction. Philadelphia, PA: Lippincott-Raven Publishers.
6.
go back to reference Heinrichs, D. W., Hanlon, T. E., & Carpenter, W. T. (1984). The quality of life scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin, 10, 388–398.PubMedCrossRef Heinrichs, D. W., Hanlon, T. E., & Carpenter, W. T. (1984). The quality of life scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin, 10, 388–398.PubMedCrossRef
7.
go back to reference Cramer, J., Rosenheck, R., Xu, W., Henderson, W., Thomas, J., & Charney, D. (2001). Department of Veterans Affairs Cooperative Study Group on Clozapine in refractory schizophrenia. Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophrenia Bulletin, 27, 227–234.PubMedCrossRef Cramer, J., Rosenheck, R., Xu, W., Henderson, W., Thomas, J., & Charney, D. (2001). Department of Veterans Affairs Cooperative Study Group on Clozapine in refractory schizophrenia. Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophrenia Bulletin, 27, 227–234.PubMedCrossRef
8.
go back to reference Lipkovich, I. A., Deberdt, W., Csernansky, J. G., Buckley, P., Peuskens, J., Kollack-Walker, S., et al. (2009). Defining “good” and “poor” outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach. Psychiatry Research, 170, 161–167.PubMedCrossRef Lipkovich, I. A., Deberdt, W., Csernansky, J. G., Buckley, P., Peuskens, J., Kollack-Walker, S., et al. (2009). Defining “good” and “poor” outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach. Psychiatry Research, 170, 161–167.PubMedCrossRef
9.
go back to reference Stahl, S. M., Malla, A., Newcomer, J. W., Potkin, S. G., Weiden, P. J., Harvey, P. D., et al. (2010). A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: A 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. Journal of Clinical Psychopharmacology, 30, 425–430.PubMedCrossRef Stahl, S. M., Malla, A., Newcomer, J. W., Potkin, S. G., Weiden, P. J., Harvey, P. D., et al. (2010). A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: A 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. Journal of Clinical Psychopharmacology, 30, 425–430.PubMedCrossRef
10.
go back to reference Leucht, S., Kane, J. M., Kissling, W., Hamann, J., Etschel, E., & Engel, R. R. (2005). What does the PANSS mean? Schizophrenia Research, 79, 231–238.PubMedCrossRef Leucht, S., Kane, J. M., Kissling, W., Hamann, J., Etschel, E., & Engel, R. R. (2005). What does the PANSS mean? Schizophrenia Research, 79, 231–238.PubMedCrossRef
11.
go back to reference Bilker, W. B., Brensinger, C., Kurtz, M. M., Kohler, C., Gur, R. C., Siegel, S. J., et al. (2003). Development of an abbreviated schizophrenia quality of life scale using a new method. Neuropsychopharmacology, 28, 773–777.PubMedCrossRef Bilker, W. B., Brensinger, C., Kurtz, M. M., Kohler, C., Gur, R. C., Siegel, S. J., et al. (2003). Development of an abbreviated schizophrenia quality of life scale using a new method. Neuropsychopharmacology, 28, 773–777.PubMedCrossRef
12.
go back to reference Detke, H.C., Weiden, P.J., Llorca, P.M., Choukour, M., Watson, S.B., Brunner, E., et al. (2011). Open label comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized study in outpatients with schizophrenia. Presented at the 13th International Congress on Schizophrenia Research, April 2011, Colorado Springs, Colorado, USA [Abstract] Schizophrenia Bulletin 37 (Supplement 1), 300. Detke, H.C., Weiden, P.J., Llorca, P.M., Choukour, M., Watson, S.B., Brunner, E., et al. (2011). Open label comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized study in outpatients with schizophrenia. Presented at the 13th International Congress on Schizophrenia Research, April 2011, Colorado Springs, Colorado, USA [Abstract] Schizophrenia Bulletin 37 (Supplement 1), 300.
13.
go back to reference Bryson, G., Lysaker, P., & Bell, M. (2002). Quality of life benefits of paid work activity in schizophrenia. Schizophrenia Bulletin, 28, 249–257.PubMedCrossRef Bryson, G., Lysaker, P., & Bell, M. (2002). Quality of life benefits of paid work activity in schizophrenia. Schizophrenia Bulletin, 28, 249–257.PubMedCrossRef
14.
go back to reference Simon-Abbadi, S., Guelfi, J. D., & Ginestet, D. (1999). Psychometric qualities of the French version of the Heinrichs Quality of Life Rating Scale. European Psychiatry, 14, 386–391.PubMedCrossRef Simon-Abbadi, S., Guelfi, J. D., & Ginestet, D. (1999). Psychometric qualities of the French version of the Heinrichs Quality of Life Rating Scale. European Psychiatry, 14, 386–391.PubMedCrossRef
15.
go back to reference Kaneda, Y., Imakura, A., Fujii, A., & Ohmori, T. (2002). Schizophrenia Quality of Life Scale: Validation of the Japanese version. Psychiatry Research, 113, 107–113.PubMedCrossRef Kaneda, Y., Imakura, A., Fujii, A., & Ohmori, T. (2002). Schizophrenia Quality of Life Scale: Validation of the Japanese version. Psychiatry Research, 113, 107–113.PubMedCrossRef
16.
go back to reference Ritsner, M., Kurs, R., Ratner, Y., & Gibel, A. (2005). Condensed version of the Quality of Life Scale for schizophrenia for use in outcome studies. Psychiatry Research, 135, 65–75.PubMedCrossRef Ritsner, M., Kurs, R., Ratner, Y., & Gibel, A. (2005). Condensed version of the Quality of Life Scale for schizophrenia for use in outcome studies. Psychiatry Research, 135, 65–75.PubMedCrossRef
17.
go back to reference Cramer, J. A., Rosenheck, R., Xu, W., Thomas, J., Henderson, W., & Charney, D. S. (2000). Quality of life in schizophrenia: A comparison of instruments. Schizophrenia Bulletin, 26, 659–666.PubMedCrossRef Cramer, J. A., Rosenheck, R., Xu, W., Thomas, J., Henderson, W., & Charney, D. S. (2000). Quality of life in schizophrenia: A comparison of instruments. Schizophrenia Bulletin, 26, 659–666.PubMedCrossRef
18.
go back to reference Ware, J. E., Jr, Snow, K. K., Kosinski, M., & Gandek, B. (1993). SF-36 health survey manual and interpretation guide. Boston: The Health Institute, New England Medical Center. Ware, J. E., Jr, Snow, K. K., Kosinski, M., & Gandek, B. (1993). SF-36 health survey manual and interpretation guide. Boston: The Health Institute, New England Medical Center.
20.
go back to reference Tunis, S. L., Croghan, T. W., Heilman, D. K., Johnstone, B. M., & Obenchain, R. L. (1999). Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. Medical Care, 37, 678–691.PubMedCrossRef Tunis, S. L., Croghan, T. W., Heilman, D. K., Johnstone, B. M., & Obenchain, R. L. (1999). Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. Medical Care, 37, 678–691.PubMedCrossRef
21.
go back to reference Kleinman, L., Lieberman, J., Dube, S., Mohs, R., Zhao, Y., Kinon, B., et al. (2009). Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function. Schizophrenia Research, 107, 275–285.PubMedCrossRef Kleinman, L., Lieberman, J., Dube, S., Mohs, R., Zhao, Y., Kinon, B., et al. (2009). Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function. Schizophrenia Research, 107, 275–285.PubMedCrossRef
22.
go back to reference Kind, P., Hardman, G., & Macran, S. (1999). UK Population Norms for EQ-5D. Discussion paper 172. Centre for Health Economics, University of York, York, 1–98. Kind, P., Hardman, G., & Macran, S. (1999). UK Population Norms for EQ-5D. Discussion paper 172. Centre for Health Economics, University of York, York, 1–98.
23.
go back to reference Rabin, R., & de Charro, F. (2001). EQ-5D: A measure of health status from the EuroQol Group. Annals of Medicine, 33, 337–343.PubMedCrossRef Rabin, R., & de Charro, F. (2001). EQ-5D: A measure of health status from the EuroQol Group. Annals of Medicine, 33, 337–343.PubMedCrossRef
24.
go back to reference Prieto, L., Novick, D., Sacristán, J. A., Edgell, E. T., Alonso, J., & SOHO Study Group. (2003). A Rasch model analysis to test the cross-cultural validity of the EuroQoL-5D in the Schizophrenia Outpatient Health Outcomes Study. Acta Psychiatrica Scandinavica Supplement, 416, 24–29.CrossRef Prieto, L., Novick, D., Sacristán, J. A., Edgell, E. T., Alonso, J., & SOHO Study Group. (2003). A Rasch model analysis to test the cross-cultural validity of the EuroQoL-5D in the Schizophrenia Outpatient Health Outcomes Study. Acta Psychiatrica Scandinavica Supplement, 416, 24–29.CrossRef
25.
go back to reference König, H. H., Roick, C., & Angermeyer, M. C. (2007). Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders. European Psychiatry, 22, 177–187.PubMedCrossRef König, H. H., Roick, C., & Angermeyer, M. C. (2007). Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders. European Psychiatry, 22, 177–187.PubMedCrossRef
26.
go back to reference Liu-Seifert, H., Ascher-Svanum, H., Osuntokun, O., Jen, K. Y., & Gomez, J. C. (2011). Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics. BioMed Central Psychiatry, 11, 87.PubMedCrossRef Liu-Seifert, H., Ascher-Svanum, H., Osuntokun, O., Jen, K. Y., & Gomez, J. C. (2011). Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics. BioMed Central Psychiatry, 11, 87.PubMedCrossRef
27.
go back to reference Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261–276.PubMedCrossRef Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261–276.PubMedCrossRef
28.
go back to reference Kay, S. R., Opler, L. A., & Lindenmayer, J. P. (1989). The positive and negative syndrome scale (PANSS): Rationale and standardization. British Journal of Psychiatry, 155(Suppl. 7), 59–65. Kay, S. R., Opler, L. A., & Lindenmayer, J. P. (1989). The positive and negative syndrome scale (PANSS): Rationale and standardization. British Journal of Psychiatry, 155(Suppl. 7), 59–65.
29.
go back to reference Kay, S. R., & Sevy, S. (1990). Pyramidal model of schizophrenia. Schizophrenia Bulletin, 16, 537–545.PubMedCrossRef Kay, S. R., & Sevy, S. (1990). Pyramidal model of schizophrenia. Schizophrenia Bulletin, 16, 537–545.PubMedCrossRef
30.
go back to reference Kay, S. R. (1991). Positive and negative syndromes in schizophrenia. Assessment and research. New York: Brunner/Mazel. Kay, S. R. (1991). Positive and negative syndromes in schizophrenia. Assessment and research. New York: Brunner/Mazel.
31.
go back to reference Lançon, C., Auquier, P., Nayt, G., & Reine, G. (2000). Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS). Schizophrenia Research, 42, 231–239.PubMedCrossRef Lançon, C., Auquier, P., Nayt, G., & Reine, G. (2000). Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS). Schizophrenia Research, 42, 231–239.PubMedCrossRef
32.
go back to reference Jäger, M., Schmauss, M., Laux, G., Pfeiffer, H., Naber, D., Schmidt, L. G., et al. (2009). Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study. European Psychiatry, 24, 501–506.PubMedCrossRef Jäger, M., Schmauss, M., Laux, G., Pfeiffer, H., Naber, D., Schmidt, L. G., et al. (2009). Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study. European Psychiatry, 24, 501–506.PubMedCrossRef
33.
go back to reference Van den Oord, E. J., Rujescu, D., Robles, J. R., Giegling, I., Birrell, C., Bukszár, J., et al. (2006). Factor structure and external validity of the PANSS revisited. Schizophrenia Research, 82, 213–223.PubMedCrossRef Van den Oord, E. J., Rujescu, D., Robles, J. R., Giegling, I., Birrell, C., Bukszár, J., et al. (2006). Factor structure and external validity of the PANSS revisited. Schizophrenia Research, 82, 213–223.PubMedCrossRef
34.
go back to reference Novick, D., Haro, J. M., Suarez, D., Vieta, E., & Naber, D. (2009). Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophrenia Research, 108, 223–230.PubMedCrossRef Novick, D., Haro, J. M., Suarez, D., Vieta, E., & Naber, D. (2009). Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophrenia Research, 108, 223–230.PubMedCrossRef
35.
go back to reference Breiman, L., Friedman, J. H., Olshen, R. A., & Stone, C. J. (1984). Classification and regression trees. Calif., USA: Wadsworth, Inc. Breiman, L., Friedman, J. H., Olshen, R. A., & Stone, C. J. (1984). Classification and regression trees. Calif., USA: Wadsworth, Inc.
36.
go back to reference Harvey, P. D., & Bellack, A. S. (2009). Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept? Schizophrenia Bulletin, 35, 300–306.PubMedCrossRef Harvey, P. D., & Bellack, A. S. (2009). Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept? Schizophrenia Bulletin, 35, 300–306.PubMedCrossRef
37.
go back to reference Ritsner, M.S., Arbitman, M., Lisker, A., & Ponizovsky, A.M. (2011). Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorder II. Predictive value of psychosocial factors. Quality of Life Research Oct 2 [Epub ahead of print]. Ritsner, M.S., Arbitman, M., Lisker, A., & Ponizovsky, A.M. (2011). Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorder II. Predictive value of psychosocial factors. Quality of Life Research Oct 2 [Epub ahead of print].
38.
go back to reference Kilian, R., Matschinger, H., Becker, T., & Angermeyer, M. C. (2003). A longitudinal analysis of the impact of social and clinical characteristics on the costs of schizophrenia treatment. Acta Psychiatrica Scandinavica, 107, 351–360.PubMedCrossRef Kilian, R., Matschinger, H., Becker, T., & Angermeyer, M. C. (2003). A longitudinal analysis of the impact of social and clinical characteristics on the costs of schizophrenia treatment. Acta Psychiatrica Scandinavica, 107, 351–360.PubMedCrossRef
39.
go back to reference Mohamed, S., Rosenheck, R., Swartz, M., Stroup, S., Lieberman, J. A., & Keefe, R. S. (2008). Relationship of cognition and psychopathology to functional impairment in schizophrenia. American Journal of Psychiatry, 165, 978–987.PubMedCrossRef Mohamed, S., Rosenheck, R., Swartz, M., Stroup, S., Lieberman, J. A., & Keefe, R. S. (2008). Relationship of cognition and psychopathology to functional impairment in schizophrenia. American Journal of Psychiatry, 165, 978–987.PubMedCrossRef
40.
go back to reference Brissos, S., Dias, V. V., Balanzá-Martinez, V., Carita, A. I., & Figueira, M. L. (2011). Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance. Schizophrenia Research, 129, 133–136.PubMedCrossRef Brissos, S., Dias, V. V., Balanzá-Martinez, V., Carita, A. I., & Figueira, M. L. (2011). Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance. Schizophrenia Research, 129, 133–136.PubMedCrossRef
41.
go back to reference Erickson, M., Jaafari, N., & Lysaker, P. (2011). Insight and negative symptoms as predictors of functioning in a work setting in patients with schizophrenia. Psychiatry Research, 189, 161–165.PubMedCrossRef Erickson, M., Jaafari, N., & Lysaker, P. (2011). Insight and negative symptoms as predictors of functioning in a work setting in patients with schizophrenia. Psychiatry Research, 189, 161–165.PubMedCrossRef
42.
go back to reference Llorca, P.M., Blanc, O., Samalin, L., Bosia, M., Cavallaro, R. & on behalf of the EGOFORS Initiative (2011). Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling. European Psychiatry Jun. 29 [Epub ahead of print]. Llorca, P.M., Blanc, O., Samalin, L., Bosia, M., Cavallaro, R. & on behalf of the EGOFORS Initiative (2011). Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling. European Psychiatry Jun. 29 [Epub ahead of print].
Metadata
Title
Empirically driven definitions of “good,” “moderate,” and “poor” levels of functioning in the treatment of schizophrenia
Authors
Haya Ascher-Svanum
Diego Novick
Josep Maria Haro
Jaume Aguado
Zhanglin Cui
Publication date
01-10-2013
Publisher
Springer Netherlands
Published in
Quality of Life Research / Issue 8/2013
Print ISSN: 0962-9343
Electronic ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-012-0335-z

Other articles of this Issue 8/2013

Quality of Life Research 8/2013 Go to the issue